Earlier Surgical Intervention for Mitral Valve Disease Is Better for Most Patients
Trends over 25 years show less invasive surgical repair and shorter
Chicago, June 9, 2015
A more aggressive approach to treating degenerative mitral valve disease, using earlier surgical intervention and less invasive techniques, is more beneficial to the patient than “watchful waiting,” according to an article in the June 2015 issue of The Annals of Thoracic Surgery.
- Earlier surgical intervention using less invasive surgical techniques is better than watchful waiting for patients with degenerative mitral valve disease.
- Over the 25 years observed, mortality rates remained low, hospital length of stay was shorter, and surgical repair became less invasive in the latter years of the study.
- Researchers said the key to successful treatment is a timely referral for surgical intervention at an advanced repair center with highly skilled heart teams.
Degenerative mitral valve disease is irreversible. It eventually leads to regurgitation (blood leaking backwards through the valve) and heart failure. While surgical treatment of the disease has evolved, there is still debate about the value of watchful waiting versus early surgical repair for patients without symptoms.
Farhang Yazdchi, MD, MS, and colleagues, from the Cleveland Clinic in Ohio, assessed trends in patient characteristics, timing of intervention, and surgical techniques for mitral valve regurgitation by reviewing the records of 5,902 patients over a 25-year period (January 1, 1985 to January 1, 2011).
They found that improved technology and earlier intervention have led to more patients benefitting from less invasive surgical repair before suffering from disease symptoms, such as atrial fibrillation (irregular, often rapid heart rate) or heart failure.
“Surgery is almost unavoidable in patients with severe degenerative mitral valve regurgitation. Our study has shown that the key to successful treatment is a timely referral for surgical intervention at an advanced repair center with highly skilled heart teams,” said Dr. Yazdchi.
The researchers found that patients who were treated in the latter years of the study (2005-2011) were released from the hospital about 2 days sooner than those treated in the earliest years of the study (1985-1997). Two main reasons for the shortened stay were fewer full sternotomies (large chest incisions)—25% in the latter years vs. 93% in the earliest years—and more patients were asymptomatic—44% in the latter years vs. 25% in the earliest years.
“Successful mitral valve repair at the Cleveland Clinic has reached a level of almost 100%, while mortality rates have remained extremely low and hospital length of stay shortened,” said Dr. Yazdchi. “Patients who are diagnosed with severe mitral valve regurgitation should seek surgical consultation sooner rather than later, even if they are not having any symptoms.
Notes for editors
Increasing Disadvantage of “Watchful Waiting” for Repairing Degenerative Mitral Valve Disease
doi:10.1016/j.athoracsur.2015.01.065 The Annals of Thoracic Surgery published by Elsevier. http://www.sciencedirect.com/science/article/pii/S0003497515002167
Full text of the article is available to credentialed journalists upon request; contact Cassie McNulty email@example.com at +1 312 202 5865
About The Annals of Thoracic Surgery
The Annals of Thoracic Surgery is the official journal of STS and the Southern Thoracic Surgical Association. Founded in 1964, The Society of Thoracic Surgeons is a not-for-profit organization representing more than 6,800 cardiothoracic surgeons, researchers, and allied health care professionals worldwide who are dedicated to ensuring the best possible outcomes for surgeries of the heart, lung, and esophagus, as well as other surgical procedures within the chest. The Society’s mission is to enhance the ability of cardiothoracic surgeons to provide the highest quality patient care through education, research, and advocacy.
Elsevier is a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge. Today, we’re committed to bringing that rigor to a new generation of platforms. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 39,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com
Media Relations Manager STS
+1 312 202 5865